As shown in Table 1, participants who received prior ADT had a higher proportion of radiotherapy as definitive treatment (80.0% vs 47.8%; P < .001) and had more aggressive prostate cancer features at time of local treatment than the no prior ADT group, including higher PSA levels at diagnosis (median 12.1 vs 9.0 ng/mL; P < .001) and higher percentage of T3 disease (38.4% vs 25.0%; P = .007). The gene discussed is KLK3; the disease is prostate cancer.